REGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript

Ken Mills: Vit, you want to chime in on this one?

Vit Vasista: Sure. Thanks, Mani. I think that as you’re thinking about that $100 million, it would be not 100% linear as much as it slowly gets split into our operating plan going forward. Some of it will be a little bit lumpy as we start to discontinue programs. And then obviously, with that 15% headcount reduction, that’s a little bit more front-end loaded. And then, as we think about OpEx, I would start to be looking at the models and determine what’s the appropriate kind of run rate, what I’ve seen, looking at different analyst models as their estimates for OpEx seems to be a lot higher than what we’re tracking against. And I think coming out of this quarter into next year, you’ll have a better idea of what the run rate is on an OpEx perspective.

And then on the other side of 2025, obviously, with the non-dilutive capital that we’re talking about and we have the opportunity to possibly the markets will unlock finally. I think post 2025, we’re going to still maintain our discipline as it relates to OpEx, but we’ll also have to some moving programs forward as they become commercial opportunities then also start to think about our pipeline going forward.

Mani Foroohar: That’s helpful. Thanks. I’ll hop off.

Operator: Thank you. This concludes today’s conference call. Thank you for participating. You may now disconnect.